Press Release

Grupo Biotoscana announces closing of Sale of Control

Sale of Control – Closing   Montevidéu, November 29th, 2019 – BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading […]

Grupo Biotoscana announces change in management

Grupo Biotoscana announces change in management Montevideo, October 21st, 2019 – BIOTOSCANA INVESTMENTS S.A. today announced the appointment of Mr. […]

Approval of CRESEMBA® and ZEVTERA® in Peru

Approval of CRESEMBA® and ZEVTERA® in Peru Grupo Biotoscana announces first approval of antifungal CRESEMBA® in Latam and approval of […]

New regulatory approvals

Grupo Biotoscana announces new approvals Montevideo, Uruguay October 4, 2018 – BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a […]

Grupo Biotoscana announces change in management

Montevideo, Uruguay August 31, 2018 – BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin […]

Approval of CRESEMBA® and ZEVTERA® in Peru

Grupo Biotoscana announces first approval of antifungal CRESEMBA® in Latam and approval of antibiotic ZEVTERA® in Peru Montevideo, Uruguay, June […]

Extension of agreement with Gilead

Grupo Biotoscana announces new agreement with gilead for the Andean region Montevideo, Uruguay, May 10, 2018. GBT-Grupo Biotoscana (B3: GBIO33), […]

Termination of contract with Actelion

Grupo Biotoscana announces termination of contract with Actelion Montevideo, Uruguay, March 13, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical […]

New initiatives for LENVIMA®

Grupo Biotoscana announces new initiatives for LENVIMA® Montevideo, Uruguay, March 12, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company […]

Launch of ZEVTERA® in Argentina

Grupo Biotoscana announces launch of antibiotic ZEVTERA® (ceftobiprole) in Argentina Montevideo, Uruguay, March 6, 2018. GBT-Grupo Biotoscana (B3: GBIO33), a […]

Extension of agreement with Biocad

Grupo Biotoscana announces extension of agreement with Biocad to include exclusive license for Infliximab in Colombia Montevideo, Uruguay, March 2, […]

HARVONI® approved in Brazil

Grupo Biotoscana expects to introduce the product into the market in Q2 2018. Montevideo, Uruguay, December 5, 2017. GBT-Grupo Biotoscana […]

Grupo Biotoscana acquires Laboratorio DOSA

Transaction advances GBT growth agenda and expands its therapeutic area scope into severe pulmonary pathologies Montevideo, Uruguay, November 13, 2017 […]

Grupo Biotoscana announces the launch of ABRAXANE® / ABRAXUS®

Montevideo, Uruguay, November 1, 2017 – GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that […]

Grupo Biotoscana announces corporate restructure

Montevideo, Uruguay October 24, 2017 – GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced a […]

Advent International awarded Colcapital´s recognition by its value creation impact on Grupo Biotoscana

Montevideo, Uruguay, October 24th 2017 – GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that […]

Grupo Biotoscana and EISAI sign exclusive licensing agreement for four products

GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an exclusive […]

Grupo Biotoscana expands its partnership with Gilead Sciences

Grupo Biotoscana expands its partnership with Gilead Sciences in HCV in Brazil. The new agreement extends the term for SOVALDI® […]

Grupo Biotoscana holds BDR´s opening trading ceremony at Bovespa

Extended partnership for 15 years and expand footprint to include Brazil

MONTEVIDEO, Uruguay – June, 2017 Grupo Biotoscana (GBT), a leading specialty pharmaceutical company in Latin America, announces the extension of […]

Grupo Biotoscana appoints new President and Chief Operating Officer

Grupo Biotoscana today announced that Jorge Ramos Manso joins Executive Leadership Team. Press Release: ENG | ESP | POR

Biotoscana, the local pharmaceutical company that became a Latin-American one

Dinheiro Magazine. A Page Dedicated to Economic and Financial News, Economic Indicators, Trade and Businesses in Colombia and worldwide. By […]

35th Annual J.P.Morgan Healthcare Conference

GBT Grupo Biotoscana, announces that Mariano García-Valiño, CEO, is schedule to present at the 35th Annual J. P. Morgan Healthcare […]

Grupo Biotoscana announces license agreement for two innovative anti-infective agents

Grupo Biotoscana announced today that it has entered into a supply, distribution and license agreement with Basilea Pharmaceutica International Ltd. […]

Pierre Fabre Pharmaceuticals y GBT celebran un contrato de comercialización en el campo de la oncología

Pierre Fabre Pharmaceuticals e GBT anunciaram hoje que fecharam um contrato na área da oncologia para a GBT comercializar o […]

Grupo Biotoscana to present at Jefferies 2016 Healthcare Conference

GBT Grupo Biotoscana, announces that Mariano García-Valiño, CEO, is scheduled to present at Jefferies Healthcare Conference in New York City, […]

Grupo Biotoscana to exhibit at ASCO 2016 Annual Meeting, Collective Wisdom

GBT Grupo Biotoscana, announces is planning to exhibit at the 2016 ASCO Annual Meeting. With more than 30,000 oncology professionals […]

BIOWORLD TODAY covers GBT‘s presentation at 34th Annual J.P. Morgan Healthcare Conference

BIOWORLD TODAY highlights GBT’s journey to become the first truly Latin American advanced medicines company. Access full article here.

Grupo Biotoscana to present at the 34th Annual J.P. Morgan Healthcare Conference

GBT-Grupo Biotoscana announces that Mariano García-Valiño, Chief Executive Officer, is scheduled to present at the 34th Annual J.P. Morgan Healthcare […]

Grupo Biotoscana adquire o Laboratório LKM

Transaction creates the first truly Latin America advanced medicines company. Press release.